MediLink A

MediLink Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes its proprietary TMALIN platform, which features a tumor microenvironment-activatable linker designed to improve the therapeutic window and efficacy of ADC therapies. MediLink has established high-profile global partnerships with major pharmaceutical companies including Roche, BioNTech, and Johnson & Johnson to co-develop and license its innovative pipeline. Their lead programs target well-validated and emerging cancer antigens such as HER3 and B7-H3, aiming to address unmet needs in solid tumors.